Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $10.7300 (1.08%) ($10.6450 - $10.7300) on Mon. Jun. 14, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.69% (three month average) | RSI | 83 | Latest Price | $10.7300(1.08%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 1.2% a day on average for past five trading days. | Weekly Trend | FOLD advances 8.8% a week on average for past two weeks. | Market Behavior | Rotation from value to growth for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(57%) IWO(53%) IWM(50%) XBI(50%) IWC(49%) | Factors Impacting FOLD price | FOLD will decline at least -1.345% in a week (0% probabilities). VIXM(-30%) VXX(-14%) UUP(-11%) UNG(-7%) TLT(-4%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.345% (StdDev 2.69%) | Hourly BBV | 0.7 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $10.59(1.32%) | 10 Day Moving Average | $10.14(5.82%) | 20 Day Moving Average | $9.62(11.54%) | To recent high | -0.6% | To recent low | 23.4% | Market Cap | $2.771b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |